DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.
HanX Biopharmaceuticals is planning an IPO in Hong Kong to fund clinical trials for its lead drug candidate, HX009, a bispecific antibody targeting PD-1 and CD47.